Anti-HIV-1 agents known as fusion inhibitors
target the N-HR or C-HR and disrupt their association, which prevents the virus from entering into the host cell.
, first introduced in 2003, block HIV from ever entering a patient's T cells.
Many of the patients had been taking a fusion inhibitor
called T-20, an experimental drug that will probably be approved for use soon by FDA, Miralles says.
The entry inhibitor category includes the fusion inhibitor
class, as well as two other classes: attachment inhibitors and co-receptor inhibitors.
Approved by the FDA in March 2003, FUZEON is the first and only fusion inhibitor
for the treatment of HIV and works in a way that is different from other types of anti-HIV drugs.
Roche and Trimeris currently market FUZEON(R) (enfuvirtide), the first and only fusion inhibitor
available for the treatment of HIV.
Classes of entry inhibitors include coreceptor inhibitors (these block HIV's interaction with coreceptors such as the chemokines CCR5 and CXCR4) and fusion inhibitors
(these prevent the virus from fusing with the cell membrane).
today announced the selection of two next-generation fusion inhibitor
peptides for co-development and progression into further pre- clinical studies.
China's FusoGen Pharmaceuticals has developed a new HIV fusion inhibitor
that is currently in human clinical trials.
Only one fusion inhibitor
has been approved so far, and this particular drug is expensive to manufacture and difficult to use.
The difference between the fusion inhibitor
group and the control groups was statistically significant, reported Dr.
Under this agreement, all rights and joint patents and other intellectual property rights to the next generation fusion inhibitor
peptides falling under the Research Agreement, which includes our lead drug candidate, TRI-1144, reverted to Trimeris.